Slammed with PhII flop for lead drug, Calithera lays off a third of its staffers
Calithera Biosciences will be going into the new year with only two-thirds of its staff.
The South San Francisco-based biotech is laying off “around 30 employees,” it told Endpoints News — or 35% of its total workforce — in the wake of a Phase II flop. Adding Calithera’s telaglenastat to Exelixis’ Cabometyx, the investigators concluded, failed to improve progression-free survival for patients with renal cell carcinoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.